다우존스 지수

실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
ZyVersa Therapeutics Inc (ZVSA)
ZyVersa Therapeutics Inc (ZVSA) 뉴스

ZVSA

ZyVersa Therapeutics (ZVSA)

ZyVersa Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ZVSA

1 2 3 4 5 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/15	21:35	GlobeNewswire Inc.	ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/05/15	21:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/05/15	21:25	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/05/14	20:57	GlobeNewswire Inc.	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/04/29	20:57	GlobeNewswire Inc.	ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/04/04	20:57	GlobeNewswire Inc.	ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/03/25	21:17	GlobeNewswire Inc.	ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/03/18	20:57	GlobeNewswire Inc.	ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/03/14	20:57	GlobeNewswire Inc.	ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/03/09	07:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/03/09	07:00	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/02/29	21:57	GlobeNewswire Inc.	ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/02/28	21:57	GlobeNewswire Inc.	ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/02/22	21:47	GlobeNewswire Inc.	ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/02/15	06:34	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/02/14	21:53	GlobeNewswire Inc.	ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/02/07	22:02	GlobeNewswire Inc.	ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/01/31	21:57	GlobeNewswire Inc.	ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/01/24	21:57	GlobeNewswire Inc.	ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/01/19	20:19	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/01/17	21:52	GlobeNewswire Inc.	ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/01/10	22:06	GlobeNewswire Inc.	ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/01/04	21:50	GlobeNewswire Inc.	ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2024/01/03	22:07	GlobeNewswire Inc.	ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2023/12/23	06:45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2023/12/18	22:12	GlobeNewswire Inc.	ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2023/12/14	21:01	GlobeNewswire Inc.	ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2023/12/12	06:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2023/12/09	06:44	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:ZVSA	ZyVersa Therapeutics Inc
2023/12/08	01:20	GlobeNewswire Inc.	ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes	NASDAQ:ZVSA	ZyVersa Therapeutics Inc

검색 관련기사 보기:NASDAQ:ZVSA

1 2 3 4 5 다음 >>

US Dollar vs Euro

Invesco QQQ Trust Series 1

US Dollar vs Sterling

Health Care Select Sector

US Dollar vs Yen

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관